Effect of Early Versus Late Administration of Human Recombinant Erythropoietin on Transfusion Requirements in Premature Infants: Results of a Randomized, Placebo-Controlled, Multicenter Trial

Author:

Donato Hugo1,Vain Nestor23,Rendo Pablo1,Vivas Norma4,Prudent Luis56,Larguı́a Miguel7,Digregorio Jorge8,Vecchiarelli Carmen6,Valverde Regina3,Garcı́a Cecilia2,Subotovsky Patricia5,Solana Claudio7,Gorenstein Adriana4,

Affiliation:

1. From the Clinical Research Area, Bio Sidus S. A.;

2. Department of Pediatrics, Sanatorio de la Trinidad;

3. Department of Neonatology, Sanatorio Jockey Club; and

4. Department of Neonatology, Clı́nica Independencia, Buenos Aires, Argentina.

5. Department of Neonatology, Clı́nica y Maternidad Suizo-Argentina;

6. Department of Neonatology, Sanatorio Otamendi;

7. Department of Neonatology, Clı́nica del Sol;

8. Department of Neonatology, Instituto Médico de Obstetricia;

Abstract

Objective. The administration of recombinant human erythropoietin (rHuEPO), started after the first 2 weeks of life, reduces the transfusion requirement in premature infants. However, its use throughout the first 2 weeks of life, when anemia results predominantly from phlebotomy losses, remains controversial. We investigated whether early use of rHuEPO would reduce the total transfusion requirement and/or the number of transfusions throughout the first 2 weeks of life. Methods. We randomized 114 infants with birth weight (BW) <1250 g to receive rHuEPO (1250 units/kg/week; IV; early group:n = 57) or placebo (late group:n = 57) from day 2 to day 14 of life; subsequently, all the patients received rHuEPO (750 units/kg/week, subcutaneously) for 6 additional weeks. All infants were given oral iron (6 mg/kg/day) and folic acid (2 mg/day). Results. The early group showed higher hematocrit and reticulocyte counts than the late group in the first 3 weeks of life, but there was no difference in the total number of transfusions (early: 1.8 ± 2.3 vs late: 1.8 ± 2.5 transfusion/patient) or the transfusion requirement throughout the first 2 weeks of life (early: .8 ± 1.1 vs late: .9 ± 1.3) could be demonstrated. In infants with BW <800 g and total phlebotomy losses >30 mL/kg (n = 29), a lower number of transfusions was received by infants in the early group, compared with late group, from the second week to the end of the treatment (early: 3.4 ± 1.1 vs late: 5.4 ± 3.7 transfusion/patient). No clinical adverse effects were observed. Thrombocytosis was detected during the treatment with rHuEPO in 31% of the infants. Conclusions. In the whole population, the early administration of rHuEPO induced a rise of reticulocyte counts, but not enough to reduce the transfusion requirement. The most severely ill infants (BW <800 g and phlebotomy losses >30 mL/kg) seemed to benefit from early use of rHuEPO, and this deserves additional study.

Publisher

American Academy of Pediatrics (AAP)

Subject

Pediatrics, Perinatology, and Child Health

Cited by 88 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3